Several monoclonal antibodies were developed, targeting primarily two key cytokines in the pathogenesis of psoriasis: interleukin (IL)-23 and IL-17.1 IL-17A represents the target of two biological drugs (secukinumab and ixekizumab), while IL-17A receptor is antagonized by brodalumab (1). Here, IL17A is linked to psoriasis.